In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3-6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.

中文翻译：

---

68Ga-PSMA-11 PET / CT对前列腺癌生化复发患者管理的影响。

在这项对转诊医师的前瞻性调查中，我们调查了68Ga标记的前列腺特异性膜抗原11（68Ga-PSMA-11）PET / CT是否以及如何影响生化复发（BCR）对前列腺癌患者的管理。方法：我们对医师（NCT02940262）进行了一项前瞻性调查，他们转诊了161例前列腺癌BCR患者（中位前列腺特异性抗原值为1.7 ng / mL；范围为0.05-202 ng / mL）。推荐医师在扫描前完成了一份调查问卷，以表明没有68Ga-PSMA-11 PET / CT信息的治疗计划（Q1； n = 101）；扫描后立即完成了一份问卷，以表示预期的管理变更（Q2； n = 101）；以及1到3-6个月后记录最终实施的管理（Q3； n = 56）。还可以通过电子病历检查或与患者联系（n = 45）来获得已实施的管理。结果：161名患者中有101名患者（63％）可获得完整的书面治疗策略（Q1 + Q2 +实施的管理）。其中76例（75％）的68Ga-PSMA-11 PET / CT结果为阳性。101例患者中有54例（53％）的实施管理与预扫描预期管理（Q1）不同。101名患者中有62名（61％）的扫描后预期管理（Q2）与扫描前预期管理（Q1）不同。但是，这些预期的改变在62例患者中的29例（47％）中没有得到实施。68Ga-PSMA-11 PET / CT上的盆腔淋巴结转移和盆腔外转移病（PSMA T0N1M0和PSMA T0N1M1模式）与实施的管理改变显着相关（P = 0.001和0.05）。结论：来自68Ga-PSMA-11 PET / CT的信息可导致50％以上的BCR前列腺癌患者发生管理变化（54/101; 53％）。但是，在68Ga-PSMA-11 PET / CT之后早期进行的预期管理变更通常与已实施的管理变更有所不同。